Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment
Editor's Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming's team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper insights into this study and its implications for the current status of ITP treatment, Oncology Frontier had an exclusive interview with Dr. Hou Ming. He provided a detailed overview of the current situation of ITP treatment in China and the promising future of using BTK inhibitors for ITP therapy.